As selective COX-2 inhibitors may confer increased risk of cardiovascular diseases and stroke (Trelle et al. 2011; Back et al. 2012; Martinez-Gonzalez and Badimon 2007; Sibbald 2004), there is a need to develop a non-toxic drug with potential to inhibit COX-2 and 5-LO, with therapeutic action in human cancers (Gautam et al. 2017). The gene discussed is PTGS2; the disease is stroke disorder.